查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971643

生物醫學檢測與分析服務市場：依檢測類型、技術、檢體類型、服務模式、檢測方法、最終用戶與應用分類－2026-2032年全球預測

Biomedical Testing & Analysis Services Market by Test Type, Technology, Sample Type, Service Model, Testing Method, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，生物醫學檢測和分析服務市場價值將達到 36.7 億美元，到 2026 年將成長至 39.9 億美元，到 2032 年將達到 66.5 億美元，複合年成長率為 8.82%。

主要市場統計數據
基準年 2025 36.7億美元
預計年份：2026年 39.9億美元
預測年份 2032 66.5億美元
複合年成長率 (%) 8.82%

為管理層提供的簡明概述，清楚地總結了當前影響臨床和研究環境中診斷測試和實驗室分析能力的趨勢。

生物醫學檢測和分析服務業正處於快速的科學技術進步、日益複雜的臨床問題以及不斷演變的醫療服務模式的交匯點。實驗室和診斷服務提供者需要在臨床化學、分子檢測和次世代定序領域提供更高附加價值的見解，同時保持嚴格的品質標準和營運效率。同時，從醫院網路到實驗室等終端用戶都期望獲得更快的檢測結果、更先進的分析能力以及與電子健康記錄的整合。

對技術創新、自動化和混合服務模式如何重塑檢查室能力和策略選擇進行深入分析。

過去幾年，變革性的變化重新定義了生物醫學檢測和分析服務的構思、組織和交付方式。高通量定序和數位PCR等分子技術的進步，使診斷從單標記檢測轉向多重檢測和全基因組分析，從而能夠更精準地進行疾病分層和標靶治療選擇。同時，質譜和流式細胞技術的改進拓展了表現型分析和生物標記發現的能力，使檢查室能夠以更高的特異性和靈敏度解決複雜的臨床問題。

對近期累積關稅政策如何影響整個診斷偵測網路的採購決策、供應商風險和營運韌性進行詳細評估。

政策制定者近期推出的關稅措施，為整個診斷服務生態系統的採購、資金籌措和供應鏈規劃帶來了新的複雜性。試劑、耗材和設備的進口關稅上調，並推高了實驗室和服務供應商的直接投入成本。這種成本壓力迫使許多機構重新評估其供應商組合，探索替代採購管道，並在某些情況下加快本地化策略，以降低進口波動風險。

基於全面細分的洞察闡明了測試類型、技術、最終用戶需求和檢體處理要求如何定義差異化的服務策略。

細分市場分析揭示了整個檢測組合中不同的需求促進因素和能力要求。就檢測類型而言，臨床化學檢測仍然是常規診斷的基礎，而血液學、免疫檢測、微生物學和分子診斷檢測則各自具有獨特的基礎設施、人員配備和品質保證要求。因此，實驗室必須根據每種檢測方法的特定處理能力和監管要求調整其技術專長。從技術角度來看，層析法、流式細胞技術、質譜、次世代定序和聚合酵素鏈鎖反應(PCR) 等平台的應用場景各不相同，這會影響資本配置和驗證路徑，因此，領導者需要根據其臨床和研究組合來優先考慮投資。

區域趨勢和策略考量表明，美洲、歐洲、中東、非洲和亞太地區的市場正在開闢不同的營運和商業化道路。

區域趨勢持續影響產業的競爭格局和營運模式。在美洲，活躍的臨床試驗活動、廣泛的醫院網路以及私人實驗室的強勁需求，正推動著分子診斷和高通量平台的快速普及。該地區還擁有完善的報銷系統和認證框架，這些都對服務設計、品質保證和商業化策略產生影響。同時，歐洲、中東和非洲地區呈現出多元化的格局，高水準的檢測中心零星分佈，而新興市場則需要靈活、注重成本效益的部署模式和可擴展的培訓項目，以擴大診斷服務的覆蓋範圍。

關鍵產業參與者、專業創新者和策略夥伴關係的評估狀況，會全面影響競爭定位和客戶選擇標準。

競爭格局由大規模綜合診斷公司、專業儀器製造商和靈活的合約實驗室組成。成熟的跨國公司持續投資於平台創新、全球服務網路和全面的試劑產品組合，以支持臨床檢查室和研究機構。同時，專注於定序、質譜或免疫檢測開發的專業公司憑藉差異化的性能特徵、簡化的工作流程和針對性的客戶支持，正迅速崛起，吸引著高複雜度客戶。

實驗室經營團隊和服務供應商可以實施的實用策略行動和韌性建設策略，以最佳化產能、確保供應穩定並提供臨床價值。

產業領導者應採取能夠保持營運柔軟性並同時兼顧核心競爭力與市場機會的投資組合策略。首先，應優先投資於模組化自動化和可互操作系統，從而在不增加過多資本負擔的情況下逐步擴大產能。這種方法可以降低技術過時的風險，並允許根據不斷變化的臨床需求快速調整工作流程。其次，應建構多元化的供應商策略，將與首選供應商的合作關係與替代採購方案結合，以降低關稅和物流中斷的影響。這包括探索建立區域製造夥伴關係和試劑聯盟的可能性，以穩定供應並降低成本風險。

高度透明的研究框架，結合與關鍵相關人員的直接對話、對二手資料的綜合分析和三角測量分析，確保了可操作和檢驗的見解。

本報告的調查方法結合了對檢驗部門負責人、採購經理和技術供應商的嚴謹初步訪談，以及對公開技術文獻、監管指南和行業白皮書的全面二手資料研究。初步訪談包括結構化訪談和業務流程現場觀察，旨在了解不同臨床和研究環境中的實際流程、挑戰和策略重點。二級資訊來源提供了對技術能力、檢驗要求和以往實施模式的背景理解。

策略整合強調了透過協調技術能力、營運柔軟性和夥伴關係主導能力來維持診斷領域領導地位的必要性。

生物醫學檢測和分析服務的未來將取決於高解析度診斷、整合資訊學和營運韌性的持續進步。能夠將技術投資與明確的臨床和商業應用場景進行策略性結合的實驗室和服務供應商將獲得競爭優勢。同時，供應鏈的波動性、不斷變化的關稅體係以及各地區的不同需求，都要求企業制定靈活的籌資策略和擴充性的服務模式，以應對突發衝擊和不斷變化的需求模式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依檢測類型分類的生物醫學檢測與分析服務市場

  • 臨床化學
  • 血液學
  • 免疫檢測
  • 微生物學
  • 分子診斷

第9章：生物醫學檢測與分析服務市場：依技術分類

  • 層析法
  • 流式細胞技術
  • 質譜分析
  • 次世代定序
  • 聚合酵素鏈鎖反應

第10章：依檢體類型分類的生物醫學檢測與分析服務市場

  • 血
  • 唾液
  • 組織
  • 尿

第11章：按服務模式分類的生物醫學檢測與分析服務市場

  • 內部
  • 外包

第12章：依檢測方法分類的生物醫學檢測與分析服務市場

  • 定性
  • 定量

第13章：生物醫學檢測與分析服務市場：依最終用戶分類

  • 診斷中心
  • 醫院和診所
  • 製藥公司
  • 研究所

第14章 生物醫學檢測與分析服務市場：依應用領域分類

  • 疾病診斷
  • 藥物研發
  • 基因檢測
  • 毒理學

第15章：生物醫學檢測與分析服務市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：生物醫學檢測與分析服務市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 生物醫學檢測與分析服務市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國生物醫學檢測與分析服務市場

第19章：中國生物醫學檢測分析服務市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • ICON plc
  • IQVIA Holdings Inc.
  • Laboratory Corporation of America Holdings
  • North American Science Associates LLC
  • Quest Diagnostics Incorporated
  • SGS SA
  • Thermo Fisher Scientific Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-2B5802CFE404

The Biomedical Testing & Analysis Services Market was valued at USD 3.67 billion in 2025 and is projected to grow to USD 3.99 billion in 2026, with a CAGR of 8.82%, reaching USD 6.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.67 billion
Estimated Year [2026] USD 3.99 billion
Forecast Year [2032] USD 6.65 billion
CAGR (%) 8.82%

A concise executive orientation that crystallizes the current forces shaping diagnostic testing and laboratory analysis capabilities across clinical and research environments

The biomedical testing and analysis services sector sits at the confluence of rapid scientific progress, increasing clinical complexity, and evolving healthcare delivery models. Laboratories and diagnostic providers are being asked to deliver higher-value insights across clinical chemistry, molecular assays, and next-generation sequencing while maintaining rigorous quality standards and operational efficiency. At the same time, end users from hospital networks to research laboratories expect faster turnaround, enhanced analytics, and integration with digital health records.

This environment is shaped by continuous technological innovation, rising clinical demand for personalized medicine, and pressures to optimize cost and throughput. Consequently, leaders within academic, clinical, and commercial laboratories are recalibrating investments in automation, informatics, and talent to preserve competitiveness. The objective of this executive summary is to synthesize the key dynamics affecting diagnostic service delivery, illuminate structural shifts that will define near-term strategy, and provide an actionable framework for stakeholders seeking to align capabilities with emerging clinical and commercial requirements.

An incisive synthesis of how technological advancements, automation, and hybrid service models are reshaping laboratory capabilities and strategic choices

Over the past several years, transformative shifts have redefined how biomedical testing and analysis services are conceived, organized, and delivered. Advances in molecular techniques such as high-throughput sequencing and digital PCR have moved diagnostics from single-marker assays toward multiplexed and genomic-scale interrogations, enabling more precise disease stratification and targeted therapeutic selection. In parallel, improvements in mass spectrometry and flow cytometry have expanded phenotyping and biomarker discovery capabilities, allowing laboratories to address complex clinical questions with greater specificity and sensitivity.

Operationally, automation and laboratory information management systems are converging with artificial intelligence and machine learning to streamline workflows, reduce manual error, and accelerate result interpretation. These technology-driven gains are complemented by an increasing reliance on hybrid service models where in-house capacity is augmented by specialized outsourced providers for high-complexity or low-volume assays. As a result, organizations must now balance investments in core infrastructure with strategic partnerships that preserve flexibility while meeting evolving regulatory, reimbursement, and quality requirements. Together, these shifts demand a reimagined strategic playbook for diagnostic leaders seeking to capture clinical value and operational resilience.

A detailed appraisal of how recent cumulative tariff policies are influencing procurement decisions, supplier risk, and operational resilience across diagnostic testing networks

Recent tariff actions implemented by policymakers have introduced a new layer of complexity for procurement, capital acquisition, and supply chain planning across the diagnostic services ecosystem. Increases in import duties on reagents, consumables, and instrumentation have elevated direct input costs for laboratories and testing service providers. This cost pressure has prompted many organizations to reassess supplier portfolios, seek alternative sourcing corridors, and, in some instances, accelerate localization strategies to mitigate exposure to import volatility.

Beyond direct cost effects, tariffs have influenced vendor contracting behaviors and lead-time expectations, prompting some manufacturers to reconfigure distribution networks or prioritize shipments in response to shifting demand. For laboratory operators, the cumulative effect has been a reinterpretation of inventory policies, a renewed focus on supplier risk assessment, and a drive to rationalize instrument footprints to concentrate high-throughput testing on the most cost-effective platforms. Importantly, these dynamics have also catalyzed negotiations with commercial partners over pricing, rebate structures, and service terms, as buyers pursue predictable total cost of ownership while preserving quality and compliance standards.

Comprehensive segmentation-driven insights that clarify how test types, technologies, end-user needs, and sample handling requirements define differentiated service strategies

Segmentation insights reveal differentiated demand drivers and capability requirements across testing portfolios. When considering test type differentiation, clinical chemistry remains foundational for routine diagnostics while hematology, immunoassay, microbiology, and molecular diagnostics each impose discrete infrastructure, staffing, and quality assurance demands; laboratories must therefore match technical competencies to the unique throughput and regulatory profiles of each modality. From a technology perspective, platforms such as chromatography, flow cytometry, mass spectrometry, next-generation sequencing, and polymerase chain reaction occupy distinct use cases that influence capital allocation and validation pathways, requiring leaders to prioritize investments that align with their clinical and research mix.

End user segmentation underscores varied service expectations: diagnostic centers prioritize throughput and cost efficiency, hospitals and clinics balance rapid turnaround with integration into clinical workflows, pharmaceutical companies demand rigorous traceability and compliance for trial support, and research laboratories emphasize flexibility and innovation adoption. Application-based distinctions further refine requirements, as disease diagnosis, drug development, genetic testing, and toxicology each demand different sensitivity, specificity, and reporting capabilities. Sample type considerations are material in operational planning because blood, saliva, tissue, and urine each require unique pre-analytic handling and storage protocols that affect supply chains and test validity. Service model choices between in-house and outsourced arrangements determine control over quality and cost, while testing method classification into qualitative and quantitative formats impacts validation approaches, regulatory submissions, and downstream analytics. Integrating these segmentation layers helps stakeholders design services that meet end-user expectations while managing cost, compliance, and scalability.

Regional dynamics and strategic considerations that illustrate how the Americas, Europe Middle East & Africa, and Asia-Pacific markets shape distinct operational and commercialization pathways

Regional dynamics continue to shape the competitive and operational contours of the industry. In the Americas, robust clinical trial activity, expansive hospital networks, and strong private-laboratory demand drive sophisticated adoption of molecular and high-throughput platforms. This region also exhibits advanced reimbursement ecosystems and established accreditation frameworks, which influence service design, quality assurance, and commercialization strategies. In contrast, the Europe, Middle East & Africa region presents a heterogeneous landscape where pockets of high-capability centers coexist with emerging markets that require adaptable, cost-conscious deployment models and scalable training programs to expand diagnostic reach.

The Asia-Pacific region is notable for rapid capacity expansion, significant public and private investments in genomics and molecular diagnostics, and an active manufacturing base for reagents and devices. These factors collectively create a dynamic environment where technology adoption can accelerate but is accompanied by diverse regulatory and reimbursement pathways. Cross-region operational strategies must therefore account for differences in clinical practice patterns, supply chain linkages, and talent availability, while exploiting opportunities for regional centers of excellence to support neighboring markets and enable economies of scale in high-complexity testing.

An evaluative landscape of major industry participants, specialist innovators, and strategic partnerships that collectively influence competitive positioning and client selection criteria

Competitive landscapes are driven by a mix of large integrated diagnostics corporations, specialized instrument manufacturers, and nimble contract testing organizations. Established multinational firms continue to invest in platform innovation, global service networks, and comprehensive reagent portfolios to support clinical laboratories and research institutions. At the same time, specialist companies focused on sequencing, mass spectrometry, or immunoassay development are gaining traction by delivering differentiated performance characteristics, streamlined workflows, and targeted customer support that appeal to high-complexity customers.

Contract research organizations and laboratory outsourcing partners are expanding their service breadth to capture specialized assay volumes and provide clients with end-to-end project management, from sample logistics to data analytics. Strategic collaborations between diagnostic providers, technology vendors, and clinical stakeholders are increasingly important for accelerating validation timelines and expanding test menus. For buyers, vendor selection now involves evaluating not just analytical performance but also post-sales support, instrument uptime guarantees, regulatory assistance, and the flexibility to adapt service models to fluctuating clinical demand.

Practical strategic actions and resilience-building measures that laboratory executives and service providers can implement to optimize capability, supply stability, and clinical value delivery

Industry leaders should pursue a portfolio strategy that aligns core competencies with market opportunities while preserving operational flexibility. First, prioritize investments in modular automation and interoperable informatics that allow incremental capacity scaling without prohibitive capital burdens. This approach reduces the risk of technology obsolescence and enables rapid reconfiguration of workflows as clinical priorities shift. Next, develop diversified supplier strategies that combine preferred vendor relationships with secondary sourcing options to mitigate tariff and logistics disruptions; this includes exploring regional manufacturing partnerships or reagent consortia to stabilize supply and cost exposure.

Leaders should also formalize collaborative arrangements with specialized testing partners to manage episodic demand for niche assays and to accelerate access to new capabilities. Concurrently, invest in workforce development programs that upskill laboratory personnel in molecular techniques, data analytics, and quality management to sustain high-performance operations. Finally, integrate value-based metrics into contractual arrangements and internal KPIs, emphasizing turnaround reliability, analytic accuracy, and clinical impact to guide continuous improvement and demonstrate the return on diagnostic investments.

A transparent research framework that integrates primary stakeholder engagement, secondary literature synthesis, and triangulated analysis to ensure actionable and validated insights

The research approach for this report combined rigorous primary engagement with laboratory leaders, procurement managers, and technology vendors alongside comprehensive secondary research into published technical literature, regulatory guidance, and industry white papers. Primary interactions included structured interviews and operational walkthroughs to capture real-world process flows, pain points, and strategic priorities across diverse clinical and research settings. Secondary sources informed the contextual understanding of technological capabilities, validation requirements, and historical adoption patterns.

Data synthesis employed triangulation across qualitative insights and documented evidence to ensure robustness of conclusions. Analytical steps included mapping technology use cases to end-user requirements, evaluating supplier ecosystems for resilience factors, and assessing regional nuances in regulatory and reimbursement environments. Quality assurance for the research included cross-validation of key findings with subject-matter experts and review against contemporary peer-reviewed and regulatory publications to maintain accuracy and relevance for decision-makers.

A strategic synthesis that reinforces the imperative for alignment between technical capability, operational flexibility, and partnership-driven capacity to sustain diagnostic leadership

The trajectory of biomedical testing and analysis services is defined by a persistent push toward higher-resolution diagnostics, integrated informatics, and operational resilience. Laboratories and testing service providers that strategically align technology investments with clearly defined clinical and commercial use cases will secure competitive advantage. At the same time, supply chain volatility, shifting tariff regimes, and heterogeneous regional requirements necessitate flexible sourcing strategies and scalable service models that can adapt to episodic shocks and evolving demand patterns.

Ultimately, success will depend on the ability to combine technical excellence with pragmatic operational design: validating high-performance platforms, ensuring robust sample management, cultivating cross-disciplinary talent, and forging partnerships that extend capacity without undermining quality. By taking a deliberate, segmentation-aware approach to capability development and regional deployment, organizations can better position themselves to deliver reliable, clinically meaningful testing services that support patient care and research progress.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biomedical Testing & Analysis Services Market, by Test Type

  • 8.1. Clinical Chemistry
  • 8.2. Hematology
  • 8.3. Immunoassay
  • 8.4. Microbiology
  • 8.5. Molecular Diagnostics

9. Biomedical Testing & Analysis Services Market, by Technology

  • 9.1. Chromatography
  • 9.2. Flow Cytometry
  • 9.3. Mass Spectrometry
  • 9.4. Next Generation Sequencing
  • 9.5. Polymerase Chain Reaction

10. Biomedical Testing & Analysis Services Market, by Sample Type

  • 10.1. Blood
  • 10.2. Saliva
  • 10.3. Tissue
  • 10.4. Urine

11. Biomedical Testing & Analysis Services Market, by Service Model

  • 11.1. In-House
  • 11.2. Outsourced

12. Biomedical Testing & Analysis Services Market, by Testing Method

  • 12.1. Qualitative
  • 12.2. Quantitative

13. Biomedical Testing & Analysis Services Market, by End User

  • 13.1. Diagnostic Centers
  • 13.2. Hospitals And Clinics
  • 13.3. Pharmaceutical Companies
  • 13.4. Research Laboratories

14. Biomedical Testing & Analysis Services Market, by Application

  • 14.1. Disease Diagnosis
  • 14.2. Drug Development
  • 14.3. Genetic Testing
  • 14.4. Toxicology

15. Biomedical Testing & Analysis Services Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Biomedical Testing & Analysis Services Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Biomedical Testing & Analysis Services Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Biomedical Testing & Analysis Services Market

19. China Biomedical Testing & Analysis Services Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Charles River Laboratories International, Inc.
  • 20.6. Danaher Corporation
  • 20.7. Eurofins Scientific SE
  • 20.8. ICON plc
  • 20.9. IQVIA Holdings Inc.
  • 20.10. Laboratory Corporation of America Holdings
  • 20.11. North American Science Associates LLC
  • 20.12. Quest Diagnostics Incorporated
  • 20.13. SGS SA
  • 20.14. Thermo Fisher Scientific Inc.
  • 20.15. Thermo Fisher Scientific Inc.
  • 20.16. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY IN-HOUSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY IN-HOUSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY OUTSOURCED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY OUTSOURCED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY OUTSOURCED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY QUALITATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY QUALITATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY QUALITATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY QUANTITATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY QUANTITATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY QUANTITATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TOXICOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TOXICOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TOXICOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. GCC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GCC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. GCC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. GCC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 166. GCC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 167. GCC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. GCC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. G7 BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. G7 BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. G7 BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. G7 BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 190. G7 BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 191. G7 BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. G7 BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. NATO BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. NATO BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. NATO BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. NATO BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. NATO BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 198. NATO BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 199. NATO BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. NATO BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)